TipRanks on MSN
Nasus Pharma initiated with a Buy at Laidlaw
Laidlaw analyst Yale Jen initiated coverage of Nasus Pharma (NSRX) with a Buy rating and $22 price target The firm says Nasus is a mid-clinical ...
Nasus Pharma Ltd (NYSE:NSRX) has filed to raise $11 million in an IPO of its ordinary shares, according to SEC F-1 registration information. The company is developing an intranasal powder spray for ...
Nasus Pharma has filed for an initial public offering. The pharmaceutical company plans to offer 1 million units at $10 to $12 apiece for total proceeds of up to $12 million, according to a filing ...
LeagueFeed on MSN
Unraveling the Rivalry: Why Does Renekton Hate Nasus?
In the expansive universe of League of Legends, few stories capture the imagination quite like the bitter enmity between ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback